A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors

BACKGROUND: AST1306 is an orally active irreversible small molecule inhibitor of EGFR (erbB1), HER2 (erbB2) and HER4 (erbB4) signaling. This is a phase I, open-label, dose-escalation study to evaluate the safety and tolerability, pharmacokinetics (PK), and preliminary anti-tumor effects of oral AST1...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jian, Cao, Junning, Li, Jin, Zhang, Yifan, Chen, Zhiyu, Peng, Wei, Sun, Si, Zhao, Naiqing, Wang, Jiachen, Zhong, Dafang, Zhang, Xiaofang, Zhang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007625/
https://www.ncbi.nlm.nih.gov/pubmed/24612546
http://dx.doi.org/10.1186/1756-8722-7-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007625/
https://www.ncbi.nlm.nih.gov/pubmed/24612546
http://dx.doi.org/10.1186/1756-8722-7-22

Ejemplares similares